Richard R. Kerr
Study: Robotic RP yields fewer positive margins
Prostate cancer patients who undergo robot-assisted radical prostatectomy have fewer positive surgical margins and less need for additional cancer treatments such as hormone or radiation therapy than patients undergoing open surgery, an observational study from UCLA’s Jonsson Comprehensive Cancer Center has found.
Urology Times welcomes Dr. Rosevear as board member
Urology Times is pleased to welcome Henry Rosevear, MD, to the publication’s Clinical Practice Board.
Insurers expand coverage of prostate cancer tests
The makers of the Decipher and ConfirmMDx prostate cancer tests have announced separate agreements that will expand insurance coverage for the two tests.
Prostate cancer treatment type strongest predictor of complications
The type of primary treatment received for prostate cancer—surgery or radiation therapy—is the strongest predictor of lesser-known complications such as the need for additional surgical procedures and development of secondary cancers, according to the authors of a recently published study from the University of Toronto.
Test accurately predicts prostate cancer recurrence after surgery
A 46-gene diagnostic test accurately predicted, based on biopsy specimens, which men would develop biochemical recurrence (BCR) or metastatic disease following radical prostatectomy, a recently published study found.
Bladder cancer study reveals potential drug targets
Researchers from the National Institutes of Health have identified new potential therapeutic targets for muscle-invasive bladder cancer, including important genes and pathways that are disrupted in the disease.
Test predicts prostate cancer radiation therapy failure
A genomic test capable of predicting the probability of developing metastatic prostate cancer outperformed existing clinical risk factors for predicting biochemical failure and distant metastasis following radiation therapy, researchers reported at the Genitourinary Cancers Symposium in San Francisco.
Anti-androgen’s benefit in chemo-naïve men tops prostate cancer news
Anti-androgen’s benefit in chemo-naïve men tops prostate cancer news
The androgen-receptor blocker enzalutamide (XTANDI) increases survival by 29% in men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of the disease by 81%, according to new phase III study results in men who had not previously received chemotherapy.
North Carolina urologist Dr. Hector Henry dies at 75
Hector H. Henry, II, MD, MPH, of Concord, NC, who practiced adult and pediatric urology for over 40 years, has died. He was 75.
For this urologist, three careers have been gratifying
He’s a urologist, but Daniel Shames, MD, has actually had three careers: practicing urologist, FDA official, and pharmaceutical industry consultant.

Poll